Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring… Read more
Vivos Therapeutics Inc (VVOS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.643x
Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has a cash flow conversion efficiency ratio of -1.643x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.16 Million) by net assets ($2.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vivos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Vivos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vivos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compal Broadband Networks Inc
TW:6674
|
-0.041x |
|
PT Techno9 Indonesia Tbk
JK:NINE
|
0.013x |
|
Panora Gayrimenkul Yatirim Ortakligi AS
IS:PAGYO
|
0.011x |
|
Comfort Gloves Bhd
KLSE:2127
|
0.003x |
|
Introl S.A.
WAR:INL
|
0.131x |
|
Schwälbchen Molkerei Jakob Berz AG
F:SMB
|
N/A |
|
Altigen Communications Inc
OTCQB:ATGN
|
0.054x |
|
Iondrive Ltd
AU:ION
|
-0.290x |
Annual Cash Flow Conversion Efficiency for Vivos Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Vivos Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.95 Million | $-12.69 Million | -1.596x | +94.51% |
| 2023-12-31 | $411.00K | $-11.95 Million | -29.066x | -612.43% |
| 2022-12-31 | $4.80 Million | $-19.59 Million | -4.080x | -562.18% |
| 2021-12-31 | $25.54 Million | $-15.73 Million | -0.616x | -83.50% |
| 2020-12-31 | $16.92 Million | $-5.68 Million | -0.336x | -118.50% |
| 2019-12-31 | $-2.94 Million | $-5.34 Million | 1.815x | +264.83% |
| 2018-12-31 | $4.83 Million | $-5.31 Million | -1.101x | -- |